Minimal disease activity in Gaucher disease: Criteria for definition

Molecular Genetics and Metabolism

Volumn 107, Issue 3, 2012, Pages 521-525

  Di Rocco, Maja ^a   Andria, Generoso ^b   Bembi, Bruno ^c   Carubbi, Francesca ^d   Giona, Fiorina ^e   Giuffrida, Gaetano ^f   Linari, Silvia ^g   Sibilio, Michelina ^b   Spina, Vincenzo ^h   Cappellini, Maria Domenica ⁱ  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g University Hospital of Florence   (Italy)

^h Ramazzini Hospital   (Italy)

ⁱ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Clinical domains; Disease stability; Gaucher disease; Minimal disease activity

Indexed keywords

BIOLOGICAL MARKER; CHITOTRIOSIDASE; HEMOGLOBIN; IMIGLUCERASE;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER WEIGHT; MALE; PARAMETERS; PHYSICIAN; PRIORITY JOURNAL; REMISSION; SPLEEN SIZE; THROMBOCYTE COUNT; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BLOOD PLATELETS; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HUMANS; LIVER; MACROPHAGES; MALE; MUSCLE, SKELETAL; ORGAN SIZE; OSTEONECROSIS; PLATELET COUNT; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SPLEEN; TREATMENT OUTCOME;

EID: 84867899370     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.08.009     Document Type: Article

References (55)

1. Grabowski G.A., Petsko G.A., Kolodny E.H. Gaucher disease. The Online Metabolic and Molecular Bases of Inherited Disease 2006, (www.ommbid.com), McGraw-Hill, New York, (revised July 2010).
2. Futerman A.H., van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 2004, 5:554-565.
3. Weinreb N.J., Charrow J., Andersson H.C., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5years of treatment: a report from the Gaucher Registry. Am. J. Med. 2002, 113:112-119.
4. Weinreb N., Taylor J., Cox T., et al. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am. J. Hematol. 2008, 83:890-895.
5. Coustan-Smith E., Campana D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. Best Pract. Res. Clin. Haematol. 2010, 23:347-358.
6. Pott C. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance. Semin. Hematol. 2011, 48:172-184.
7. Kirwan J., Heiberg T., Hewlett S., et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. J. Rheumatol. 2003, 30:868-872.
8. Wells G.A., Boers M., Shea B., et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J. Rheumatol. 2005, 32:2016-2024.
9. Wells G.A., Boers M., Tugwell P., et al. Low disease activity state in rheumatoid arthritis: concepts and derivations of minimal disease activity. Clin. Exp. Rheumatol. 2006, 24:52-59.
10. Wolfe F., Rasker J.J., Boers M., et al. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007, 57:935-942.
11. Di Rocco M., Giona F., Carubbi F., et al. A new severity index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica 2008, 93:1211-1218.
12. Weinreb N.J., Cappellini M.D., Cox T.M., et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet. Med. 2010, 12:44-51.
13. Fink A., Kosecoff J., Chassin M., Brook R.H. Consensus methods: characteristics and guidelines for use. Am. J. Public Health 1984, 74:979-983.
14. Zimran A., Kay A., Gelbart T., et al. Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients. Medicine 1992, 71:337-353.
15. Zimran A., Altarescu G., Rudensky B., et al. Survey of hematological aspects of Gaucher disease. Hematology 2005, 10:151-156.
16. Charrow J., Andersson H.C., Kaplan P., et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch. Intern. Med. 2000, 160:2835-2843.
17. Cox T.M. Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J. Inherit. Metab. Dis. 2001, 24:106-121.
18. Blanc B., Finch C.A., Hallberg L., et al. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech. Rep. Ser. 1968, 405:1-40.
19. Hematology - Basic Principles and Practice 2009, Churchill Livingston, an imprint of Elsevier Inc. Fifth Edition. R. Hoffman, E.J. Benz, S.J. Shattil (Eds.).
20. National Institutes of Health Consensus Conference Platelet transfusion therapy. Transfus. Med. Rev. 1987, 1:195-200.
21. Gillis S., Hyam E., Abrahamov A., et al. Platelet function abnormalities in Gaucher disease patients. Am. J. Hematol. 1999, 61:103-106.
22. Hollak C.E., Levi M., Berends F., et al. Coagulation abnormalities in type 1 Gaucher disease are due to low grade activation and can be partly restored by enzyme supplementation therapy. Br. J. Haematol. 1997, 96:470-476.
23. Hill S.C., Reinig J.W., Barranger J.A., et al. Gaucher disease: sonographic appearance of the spleen. Radiology 1986, 160:631-634.
24. Data available at, Last accessed on November 23, 2011. http://www.gaucherregistry.com.
25. Wenstrup R.J., Kacena K.A., Kaplan P., et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J. Bone Miner. Res. 2007, 22:119-126.
26. Maas M., van Kuijk C., Stoker J., et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging - initial experience. Radiology 2003, 229:554-561.
27. Robertson P.L., Maas M., Goldblatt J. Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score. Am. J. Roentgenol. 2007, 188:1521-1528.
28. Poll L.W., Koch J.A., Willers R., et al. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. Blood Cells Mol. Dis. 2002, 28:209-220.
29. Rosenthal D.I., Scott J.A., Barranger J., et al. Evaluation of Gaucher disease using magnetic resonance imaging. J. Bone Joint Surg. Am. 1986, 68:802-808.
30. Poll L.W., Koch J.A., vom Dahl S., et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 2001, 30:496-503.
31. Terk M.R., Dardashti S., Liebman H.A. Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol. 2000, 29:563-571.
32. Vlieger E.J., Maas M., Akkerman E.M., et al. Vertebra disc ratio as a parameter for bone marrow involvement and its application in Gaucher disease. J. Comput. Assist. Tomogr. 2002, 26:843-848.
33. Pastores G.M., Wallenstein S., Desnick R.J., Luckey M.M. Bone density in Type 1 Gaucher disease. J. Bone Miner. Res. 1986, 11:1801-1807.
34. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level 2004, World Health Organization, Geneva.
35. Boot R.G., van Breemen M.J., Wegdam W., et al. Gaucher disease: a model disorder for biomarker discovery. Expert Rev. Proteomics 2009, 6:411-419.
36. Hollak C.E., Maas M., Aerts J.M. Clinically relevant therapeutic endpoints in type I Gaucher disease. J. Inherit. Metab. Dis. 2001, 24:97-105.
37. Aerts J.M., Kallemeijn W.W., Wegdam W., et al. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J. Inherit. Metab. Dis. 2011, 34:605-619.
38. Hollak C.E., van Weely S., van Oers M.H., Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 1994, 93:1288-1292.
39. Guo Y., He W., Boer A.M., et al. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. J. Inherit. Metab. Dis. 1995, 18:717-722.
40. Boot R.G., van Achterberg T.A., van Aken B.E., et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol. 1999, 19:687-694.
41. Boot R.G., Hollak C.E., Verhoek M., et al. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin. Chim. Acta 2010, 411:31-36.
42. Aerts J.M., Boot R.G., Renkema G.H., et al. Molecular and biochemical abnormalities of Gaucher disease: chitotriosidase, a newly identified biochemical marker. Semin. Hematol. 1995, 32:10-13.
43. Aerts J.M., Hollak C.E., van Breemen M., et al. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr. Suppl. 2005, 94:43-46.
44. Cox T.M. Biomarkers in lysosomal storage diseases: a review. Acta Paediatr. Suppl. 2005, 94:39-42.
45. Deegan P.B., Moran M.T., McFarlane I., et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol. Dis. 2005, 35:259-267.
46. Boot R.G., Verhoek M., de Fost M., et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004, 103:33-39.
47. Cox T.M., Aerts J.M., Belmatoug N., et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J. Inherit. Metab. Dis. 2008, 31:319-336.
48. Chang K.L., Hwu W.L., Yeh H.Y., et al. CCL18 is an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency. Blood Cells Mol. Dis. 2010, 44:38-40.
49. Aerts J.M., van Breemen M.J., Bussink A.P., et al. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr. Suppl. 2008, 97:7-14.
50. van Breemen M.J., de Fost M., Voerman J.S., et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim. Biophys. Acta 2007, 1772:788-796.
51. Pavlova E.V., Deegan P.B., Tindall J., et al. Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol. Dis. 2011, 46:27-33.
52. Stein P., Yang R., Liu J., et al. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J. Inherit. Metab. Dis. 2011, 34:429-437.
53. Dekker N., van Dussen L., Hollak C.E., et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011, 118:e118-e127.
54. Cox T.M. Gaucher disease: clinical profile and therapeutic developments. Biologics 2010, 4:299-313.
55. Pastores G.M., Weinrab N.J., Aerts H., et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 2004, 41:4-14.